

DR. DEBDEEP SAMADDAR

Associate Consultant - Medical Oncology

Qualification

MBBS | MD | DM (Medical Oncology- TMH Mumbai)

Overview

Dr. Debdeep Samaddar is a dedicated Medical Oncologist associated with Manipal Hospital Broadway, Kolkata, with advanced training in the diagnosis, treatment, and comprehensive management of cancer. His clinical practice focuses on evidence-based oncology care, personalized treatment planning, chemotherapy, immunotherapy, targeted therapy, supportive care, patient counselling, and multidisciplinary cancer management. With his strong academic foundation and patient-centric approach, Dr. Samaddar aims to provide structured and compassionate cancer care for patients across different stages of the disease. Dr. Samaddar completed his DM in Medical Oncology from Tata Memorial Hospital, Mumbai, one of India’s most reputed cancer care and research institutes. He also holds an MD in Radiation Oncology from R.G. Kar Medical College and Hospital, Kolkata, and completed his MBBS from College of Medicine and Sagar Dutta Hospital, Kolkata. This strong academic background gives him a broad understanding of cancer treatment across different modalities, including systemic therapy, radiation-based treatment planning, and multidisciplinary oncology care. His dual exposure to medical oncology

and radiation oncology helps him contribute effectively to comprehensive cancer treatment planning. At Manipal Hospital Broadway, Dr. Samaddar is involved in managing a wide spectrum of cancers, including Hemato-Oncology, GI Oncology, Breast Oncology, Uro Oncology, Thoracic Oncology, and Bone & Soft Tissue Oncology. His areas of clinical and academic interest include genitourinary malignancies, plasma cell dyscrasias, sarcomas, and immuno-oncology. His approach is based on understanding each patient's cancer type, stage, biological behaviour, molecular profile, general health condition, treatment goals, and quality-of-life expectations before planning therapy. Cancer care today is highly personalized, and Dr. Samaddar follows this modern approach in his clinical practice. Two patients with the same cancer may need different treatment plans depending on disease stage, genetic mutations, biomarkers, age, organ function, co-existing medical conditions, and previous treatment history. His treatment planning focuses not only on controlling the disease but also on helping patients maintain strength, comfort, dignity, and confidence throughout their cancer journey. Dr. Samaddar believes that cancer treatment should be scientific, structured, and compassionate. A cancer diagnosis can be emotionally overwhelming for patients and families, often creating fear and uncertainty about treatment, side effects, recovery, and long-term outcomes. In his practice, he emphasizes clear communication and patient education so that patients and caregivers can understand the diagnosis, available treatment options, expected benefits, possible risks, and the importance of regular follow-up. His clinical approach includes detailed evaluation, review of biopsy and imaging reports, staging assessment, molecular or biomarker testing wherever required, systemic therapy planning, treatment monitoring, and side-effect management. Depending on the type and stage of cancer, treatment may include chemotherapy, immunotherapy, targeted therapy, hormonal therapy, or palliative systemic therapy. He also works in coordination with other specialties such as surgical oncology, radiation oncology, radiology,

pathology, gastroenterology, pulmonology, urology, orthopaedics, pain and palliative care, nutrition, and critical care whenever needed. Multidisciplinary cancer care is an important part of Dr. Samaddar's practice. Many cancers require a combination of treatment modalities. For example, a breast cancer patient may require surgery, chemotherapy, radiation therapy, hormone therapy, and long-term follow-up. A lung cancer patient may need molecular testing, targeted therapy, immunotherapy, chemotherapy, or radiation depending on the diagnosis. A sarcoma patient may require coordination between medical oncology, surgical teams, radiology, pathology, and rehabilitation services. At Manipal Hospital Broadway, Dr. Samaddar's role as a medical oncologist is to guide systemic cancer treatment while ensuring that patients receive coordinated and comprehensive care. In Hemato-Oncology, Dr. Samaddar manages cancers of the blood, bone marrow, and lymphatic system. These include leukemia, lymphoma, multiple myeloma, plasma cell disorders, and related hematological malignancies. Such conditions often require detailed investigations, including blood tests, bone marrow studies, immunophenotyping, cytogenetics, molecular testing, imaging, and risk stratification. Treatment may include chemotherapy, targeted therapy, immunotherapy-based regimens, steroids, supportive care, transfusion support, infection prevention, and long-term monitoring. Dr. Samaddar has a strong academic orientation toward plasma cell disorders, including multiple myeloma and AL amyloidosis. These diseases often require careful evaluation, repeated response assessment, and long-term treatment planning. His academic work and conference presentations in multiple myeloma and AL amyloidosis reflect his continued interest in improving understanding and outcomes in this area. In GI Oncology, Dr. Samaddar focuses on cancers of the digestive system, including cancers of the stomach, colon, rectum, liver, pancreas, gallbladder, bile duct, oesophagus, and other gastrointestinal organs. These cancers may present with symptoms such as unexplained weight loss, persistent abdominal pain,

blood in stool, jaundice, vomiting, difficulty swallowing, loss of appetite, or altered bowel habits. Treatment depends on the site, stage, tumour biology, and overall condition of the patient. GI cancer treatment often requires a coordinated approach, involving medical oncology, surgical oncology, gastroenterology, radiation oncology, radiology, pathology, and nutrition support. Some patients may need chemotherapy before surgery to shrink the tumour, while others may require chemotherapy after surgery to reduce the risk of recurrence. Advanced-stage GI cancers may require systemic therapy, targeted therapy, immunotherapy, or symptom-directed palliative treatment. Dr. Samaddar's approach focuses on individualized decision-making so that each patient receives treatment according to disease burden, treatment intent, and quality-of-life goals. In Breast Oncology, Dr. Samaddar manages patients with breast cancer across different stages of the disease. Breast cancer is one of the most common cancers among women and can have better outcomes when diagnosed early. Warning signs may include a breast lump, nipple discharge, skin dimpling, change in breast shape, nipple retraction, breast swelling, or lump in the underarm. Early evaluation and timely treatment play an important role in improving patient outcomes. Modern breast cancer treatment is highly personalized. Treatment decisions are based on tumour size, lymph node involvement, hormone receptor status, HER2 status, grade, stage, menopausal status, and recurrence risk. Some patients may need chemotherapy before surgery, while others may require surgery first followed by chemotherapy, hormone therapy, targeted therapy, or radiation therapy. Dr. Samaddar supports patients through treatment planning, therapy administration, side-effect management, counselling, and long-term follow-up. In Uro Oncology, also known as genitourinary oncology, Dr. Samaddar manages cancers of the prostate, kidney, bladder, testis, penis, and adrenal region. These cancers may present with symptoms such as blood in urine, urinary difficulty, testicular swelling, pelvic discomfort, back pain, unexplained weight loss, or bone pain in advanced disease. His

academic and clinical interest in genitourinary malignancies makes this an important part of his oncology practice. Uro oncology has seen major advances in recent years, especially with the use of immunotherapy, targeted therapy, hormone-based treatment, and newer systemic therapies. Dr. Samaddar's approach involves stage-wise evaluation, risk classification, treatment planning, coordination with urology and radiation oncology, and long-term disease monitoring. For prostate cancer, treatment may involve hormone therapy and systemic treatment options. For bladder, kidney, and testicular cancers, treatment is planned according to stage, risk category, and treatment response. In Thoracic Oncology, Dr. Samaddar focuses mainly on lung cancer and other cancers of the chest region. Lung cancer may present with symptoms such as persistent cough, blood in sputum, chest pain, breathlessness, hoarseness, unexplained weight loss, or repeated chest infections. However, some lung cancers may remain silent until they reach an advanced stage, making timely evaluation important for persistent or unexplained respiratory symptoms. Modern lung cancer management relies heavily on accurate diagnosis, staging, and molecular profiling. Some lung cancers may carry driver mutations that can be treated with targeted therapy, while others may benefit from immunotherapy or chemotherapy depending on biomarker status and overall health condition. Dr. Samaddar has contributed to research related to genomic profiling and treatment outcomes in non-small cell lung cancer, reflecting his academic involvement in this evolving field. In Bone and Soft Tissue Oncology, Dr. Samaddar manages rare and complex cancers such as osteosarcoma, Ewing sarcoma, soft tissue sarcoma, chondrosarcoma, gastrointestinal stromal tumours, and other connective tissue tumours. These cancers require precise diagnosis, expert pathology review, imaging, biopsy planning, and multidisciplinary care. Treatment depends on tumour type, grade, location, stage, operability, and patient fitness. Sarcoma care requires careful planning and multidisciplinary coordination. Treatment may

include chemotherapy, surgery, radiation therapy, targeted therapy, or a combination of these. Dr. Samaddar has academic involvement in sarcoma-related outcomes research and has presented work on relapsed Ewing sarcoma at an international rare tumour and sarcoma congress. This reflects his interest in rare and challenging cancers that need specialized evaluation and treatment planning. Along with clinical practice, Dr. Debdeep Samaddar has a strong interest in oncology research, medical writing, and academic communication. His profile includes multiple peer-reviewed publications, abstracts, poster presentations, and oral presentations at national and international oncology forums. His research work covers areas such as brain metastasis, testicular seminoma, AL amyloidosis, multiple myeloma, acute myeloid leukemia, non-small cell lung cancer, gastric cancer, and relapsed Ewing sarcoma. His academic involvement helps him stay connected with evolving treatment standards, real-world outcomes, newer therapies, and evidence-based decision-making. This research-oriented approach strengthens his clinical practice and allows him to bring updated oncology knowledge into patient care. His participation in tumour board discussions, clinical research, and collaborative care models reflects his commitment to continuous learning and comprehensive cancer management. Dr. Samaddar is also passionate about community health education and cancer awareness. Many cancers can have better outcomes when detected early, and awareness plays a major role in encouraging timely consultation. Through patient education and counselling, he aims to help people understand warning symptoms, risk factors, screening importance, available treatment options, and the value of regular follow-up. At Manipal Hospital Broadway, Kolkata, Dr. Debdeep Samaddar’s practice represents a balanced combination of advanced oncology training, multidisciplinary care, research orientation, and compassionate patient support. His focus is to provide comprehensive cancer care that is personalized, evidence-based, and aligned with each patient’s medical needs and treatment goals.

Field of Expertise

- Genitourinary malignancies
- Plasma cell dyscrasias
- Sarcomas
- Breast Oncology
- Immuno-oncology

Languages Spoken

- English
- Hindi
- Bengali

Awards & Achievements

- Advanced oncology training from Tata Memorial Hospital, Mumbai, one of India’s leading cancer care and research institutes.
- Worked as Medical Oncologist / Ad hoc Assistant Professor at Tata Memorial Hospital, Mumbai from May 2025 to April 2026.
- Experienced in managing a wide range of cancer patients, including solid tumours, blood cancers, genitourinary cancers, plasma cell disorders, sarcomas, and thoracic malignancies.
- Actively participated in multidisciplinary tumour board meetings, contributing to treatment planning and evaluation of complex cancer cases.
- Strong academic orientation in genitourinary malignancies, plasma cell dyscrasias, sarcomas, and immuno-oncology.
- Presented research at national and international oncology conferences, including ESMO Asia, International Myeloma

Society Annual Conference, Indian Myeloma Congress, ICON, and ESMO Rare Tumor and Sarcoma Congress.
- Contributed to real-world and retrospective oncology outcomes research, with multiple abstracts, posters, mini oral presentations, and peer-reviewed publications.
- Completed Clinical Research Methods and Protocol Development Workshop – AAZPIRE 2024, Mumbai.
- Completed ACLS and BLS workshop at ACTREC, Mumbai.

Talks & Publications

- Incidence and clinical profile of brain metastasis treated with whole brain radiotherapy in a tertiary hospital in eastern India: A retrospective audit, Indian Journal of Cancer, 2023.
- Is active surveillance a good treatment option for stage 1 seminoma in a developing nation? Long-term outcomes from the Indian subcontinent eCancer, 2025.
- Perception of Oncology Evaluated by Medical Students — P.O.E.M.S.: A Single Institutional Study Journal of Cancer Education, 2022.
- Genomic Profiling of Driver Gene Alterations in Patients With Non-Small Cell Lung Cancer, Patterns of Treatment and Impact on Survival Outcomes: A Single Centre Experience of More Than 1200 Patients, Clinical Lung Cancer, 2025.
- Docetaxel-oxaliplatin-capecitabine/5-fluorouracil followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil in HER2-negative advanced gastric cancers, JNCI Cancer Spectrum, 2024.
- The utility of tumour markers in detecting relapses in testicular seminoma: largest experience from a comprehensive cancer centre in India.
- Annals of Oncology, 2024.

- Clinical profile, treatment patterns, outcomes and predictors of survival in AL amyloidosis: A retrospective study from a tertiary cancer centre, Clinical Lymphoma Myeloma Leukaemia, 2025.
- Clinical outcomes and prognostic determinants in relapsed Ewing sarcoma: Real-world experience from Indian subcontinent ESMO Rare Cancers. Poster presentation at ESMO Asia 2024, Singapore
- Topic: The utility of tumour markers in detecting relapses in testicular seminoma.
- Poster presentation at International Myeloma Society Annual Conference 2025, Toronto, Canada
- Topic: Clinical profile, treatment patterns, outcomes and predictors of survival in AL amyloidosis.
- Mini Oral Presentation at Indian Myeloma Congress 2025, Kolkata
- Topic: Clinical profile and outcome of primary refractory disease in multiple myeloma.
- Mini Oral Presentation at ICON 2024, Mumbai
- Topic: Incidence, treatment pattern and clinical outcomes of acute myeloid leukaemia patients.
- Mini Oral Presentation at Indian Myeloma Congress 2026, Kochi
- Topic: Correlation of haematological response with outcome in AL amyloidosis.
- Poster presentation at ESMO Rare Tumor and Sarcoma Congress 2026, Lugano, Switzerland
- Topic: Clinical outcomes and prognostic determinants in relapsed Ewing sarcoma.